Endogenous carbon monoxide (CO) exerts anti-inflammatory effects. Tristetraprolin (TTP) is known to destabilize proinflammatory transcripts. Here we found that exogenous CO enhanced the decay of TNF-a mRNA and suppressed TNF-a expression in LPS-activated macrophages from wild-type (WT) mice. However, TTP deficiency abrogated the effects of exogenous CO. While CO treatment prior to DSS administration in WT mice significantly reduced inflammatory cytokine levels and colitis, it failed to reduce the pro-inflammatory cytokine levels and colitis in TTP knockout (KO) mice. Our results demonstrate that TTP is a key factor mediating the anti-inflammatory action of CO in DSS-induced colitis. 
Introduction
Endogenous CO is one of the three products of heme degradation created by heme oxygenase-1 (HO-1), the other two being Fe 2+ and biliverdin [1] . These byproducts have recently been shown to have strong cytoprotective effects. This is thought to result from their anti-inflammatory, anti-apoptotic, and antioxidant actions [2] . Interestingly, recent studies have shown that the exogenous application of CO or CO-releasing molecules (CORMs) can also confer protective effects in models of inflammatory stress or tissue injury [3] . In intestinal inflammation, exogenous CO reduces the severity of disease activity [4, 5] . Recently, CORMs have been used in biological systems to deliver CO in a controlled manner, while keeping carbon monoxy hemoglobin levels stable [6] . CO-RM-derived CO has been shown to inhibit various inflammatory states [7] . In particular, CO-RM ameliorates DSS-induced colitis by inhibition of neutrophil infiltration and TNF-a production [8] . Hence, CO might be a novel and important molecule in the treatment of intestinal inflammation.
Inflammatory bowel diseases (IBD) are inflammatory disorders related to a dysfunction in the innate responses to bacterial products. Multiple genetic defects have been linked to immune dysfunction [9] , but the precise pathogenesis of IBD remains unclear. Various models of experimental IBD have been developed to investigate the pathogenesis. The administration of dextran sulfate sodium (DSS) induces a reversible form of colitis in mice [10] . This model is characterized by acute tissue inflammation in the colon and mimics the pathology of human ulcerative colitis. In this colitis model, expression of pro-inflammatory cytokines is upregulated [11] . Since immuno-compromised mice lacking the T and B cell compartments remain susceptible in this model [12] , macrophages and dendritic cells (DCs) are proposed to play a central role in the pathogenesis of DSS-induced colitis. Macrophages and intestinal DCs are the first antigen presenting cells (APCs) to sense and respond to exogenous antigens or tissue injury [13] and to activate T cells and induce T cell proliferation in DSS-induced colitis [14] .
The inflammatory response has been reported to be modulated by post-transcriptional control [15] . The post-transcriptional control of inflammatory transcripts is strongly dependent on AU-rich element (ARE)-mediated mechanisms [16] . The destabilizing function of AREs is believed to be regulated by AREbinding proteins [17] . Tristetraprolin (TTP) is an ARE-binding protein that promotes degradation of a number of inflammatory mediators [18] [19] [20] . TTP-knockout mice develop severe inflammatory arthritis, autoimmune dysfunction, and myeloid hyperplasia, demonstrating the importance of TTP in limiting the inflammatory response [21] .
Here we describe a so far unanticipated role of TTP in the antiinflammatory function of CO in DSS-induced colitis. We found that TTP deficiency exacerbates disease severity and blocks the anti-inflammatory activity of CO in DSS-induced colitis. We provide evidence that CO induces the expression of TTP, and in turn, TTP plays an important role in the CO-induced antiinflammatory effect through destabilization of TNF-a transcripts.
Methods

Cells
Peripheral macrophages were isolated from wild-type (WT) and TTP knockout (KO) mice according to previously described methods [22] . Peritoneal macrophages and murine monocyte macrophage cells (RAW264.7) were cultured in DMEM supplemented with 10% FBS. Cells were exposed for 4 h to LPS (1 mg/ ml, L-2654, Sigma, USA) in the presence or absence of tricarbonyldichlororuthenium (II) dimer (CORM-2; Sigma, USA) (5, 10, 20 , and 50 mM), and TTP and TNF-a levels were determined at the end of the incubation. Inactive CORM-2 (iCORM-2) was used as a negative control [23] to assess whether the effects observed were due to the CO liberated by the CORM-2 or were caused by other components of the molecules.
Mice and Ethics Statement
TTP knockout (KO) mice were kindly provided by Dr. Perry J Blackshear (Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, USA). Mice were bred in the animal facility at the University of Ulsan and were born and housed in the same room under specific pathogen-free conditions. In all experiments, sex-and age-matched littermates were used as controls. All mice were handled in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the Immunomodulation Research Center (IRC), University of Ulsan. All animal procedures were approved by IACUC of IRC (Permit Number: UOU-2012-005). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
Dextran Sulfate Sodium (DSS)-mediated Colitis
Acute colitis was induced with 2% (w/v) dextran sulfate sodium (DSS) (36-50 kDa, MP Biomedicals) dissolved in drinking water for 7 days followed by normal drinking water until the end of the experiment. The DSS solutions were made fresh every day.
CO Inhalation Treatment
After treatment with DSS for 7 days, mice were exposed to CO at a concentration of 250 ppm in an exposure chamber (LB Science, Daejeon, Korea) at room temperature for 3 h a day for 5 days. A CO analyzer (Tongoy Control Technology, Beijing, China) was used to continuously measure the CO levels in the cage in order to maintain the CO concentration at 250 ppm. The animals were divided into three groups: a sham group, a DSSinduced colitis group, and a DSS-induced colitis group treated with CO inhalation.
Evaluation of Colitis Severity
The clinical activity score was determined daily by scoring changes in animal weight, occult blood positivity, gross bleeding, and stool consistency. We used five grades of weight loss (0, no loss or weight gain; 1, 1-5% loss; 2, 5-10% loss; 3, 10-20% loss; 4, . 20% loss), three grades of stool consistency (0, normal; 2, loose; and 4, diarrhea), and three grades of occult blood (0, negative; 2, occult blood-positive; and 4, gross bleeding). These scores were added to generate a clinical activity score ranging from 0 to 12.
After determining the clinical activity score, mice were sacrificed, the entire colon was removed from the cecum to the anus, and the colon length was measured as an indirect marker of inflammation. The distal colon was fixed in 10% buffered formalin for histological analysis. Sections 5 mm thick were prepared and stained with hematoxylin and eosin (H&E).
Determination of TNF-a Levels
The concentration of TNF-a in the supernatant of cultured cells or mucosal homogenates was analyzed using DuoSet ELISA Development Systems (R&D Systems, Minneapolis, MN, USA).
Plasmids, Transfections and Luciferase Assay
The genomic sequence of the mouse TTP gene (GenBank accession number NT_187034) was used to engineer PCR cloning primers: 59-GAGCTCTTCTATCTTTCTGTAACCCAC-39, 59-CTCGAGTGGCAGAGAGATCCATGGTGG-39. Underlined letters are restriction enzyme sites. A 1309-base pair (bp) genomic fragment containing the 59-flanking region of the TTP gene was isolated by PCR amplification from mouse genomic DNA. Construct pGL3/mTTP p-1309 contains the -1309 bp promoter region of the mouse TTP gene up to nucleotide +48 base pair (i.e., downstream from the mouse TTP mRNA cap site) inserted into the SacI and XhoI sites of the pGL3 basic vector (Promega). A pRL-SV40 Renilla luciferase construct was purchased from Promega (E2231).
RAW264.7 cells were transfected with luciferase reporter constructs using the Neon TM transfection system (Invitrogen). Lysates of the transfected cells were mixed with luciferase assay reagent (Promega), and the chemiluminescent signal was measured in a Wallac Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland). Firefly luciferase of pGL3/mTTP p-1309 was normalized to Renilla luciferase of pRL-SV40 in each sample.
Actinomycin D-based RNA Kinetic Analysis
Peritoneal macrophages were exposed to 10 mM CORM-2 (Sigma) and 1 mg/ml LPS (Sigma) for 20 min. After incubation for 24 h, cells were incubated with 5 mg/ml actinomycin D (Sigma) to stop transcription, and cells were collected at 0, 15, 30, 45, and 60 min after addition of actinomycin D and analyzed for TNF-a mRNA by quantitative RT-PCR.
Quantitative Real-time PCR and Semi-qRT-PCR
Total RNAs were extracted from cells and colon of WT and TTP KO mice using the RNeasy Mini Kit (Qiagen). For RNA kinetic analysis, 3 mg of DNase I-treated total RNA was reverse transcribed using oligo-dT and Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. qRT-PCR was performed by monitoring the increase in fluorescence in real-time of the SYBR Green dye (QIAGEN, Hilden, Germany) using StepOnePlus TM Real-time PCR systems (Applied Biosystems). Semi-qRT-PCR was performed using Taq polymerase (Solgent, Daejeon, Korea) and PCR primer pairs:
GAPDH, 59-ATGACAACTTTGGCATTGTG-39 and 59-CATACTTGGCAGGTTTCTCC-39; 18S rRNA, 59-CAGT-GAAACTGCGAATGGCT-39 and 59-TGCCTTCCTTGGATGTGGTA-39; KC (CXCL1), 59-TTGTGCGAAAAGAAGTGCAG-39 and 59-TACAAACA-CAGCCTCCCACA-39; IL-6, 59-ACAAGTCGGAGGCT-TAATTACACAT-39 and 59-TTGCCATTGCA-CAACTCTTTTC-39; TNF-a, 5 9-AGGCTGCCCCGACTACGT-39 and 59-GACTTTCTCCTGGTATGAGATAGCAAA-39; MIP-2 (CXCL2), 59-CACTCTCAAGGGCGGTCAAA-39 and 59-TAC-GATCCAGGCTTCCCGGGT-39.
Myeloperoxidase (MPO) Assay
The MPO enzyme activity in colonic tissues was analyzed using Mouse Myeloperoxidase DuoSet (R&D Systems, Minneapolis, MN).
Statistical Analysis
For statistical comparisons, p-values were determined using Student's t test.
Results
CO Induces TTP mRNA in Macrophages
CO has been reported to suppress the production of inflammatory cytokines [7] . However, the molecular basis by which CO mediates such anti-inflammatory functions is unknown. TTP enhances degradation of various inflammatory cytokines [18] [19] [20] . This prompted us to evaluate the functional link between CO and TTP in macrophages, with the hypothesis that CO increases the expression of TTP, which in turn mediates the anti-inflammatory activity of CO by enhancing the degradation of mRNAs of inflammatory cytokine genes. To test this hypothesis, we initially determined the effect of CORM-2 on the expression level of TTP in macrophages. CORM-2 treatment significantly increased TTP transcripts in a dose-dependent manner (Fig. 1A) . This effect appeared to be strictly dependent on the CO released by CORM-2, since iCORM-2, which does not liberate CO, did not have any effect on TTP level (Fig. 1A) .
The experiments above indicate that CORM-2 is able to induce TTP transcription. We next tested whether CORM-2 was able to transactivate the TTP promoter in a reporter assay. RAW264.7 cells were transiently transfected with pGL3/mTTP p-1309 construct containing the 21261 , +48 promoter region of the mouse TTP gene followed by treatment with CORM-2. CORM-2 treatment significantly stimulated the TTP promoter at 4 h after the treatment in a dose-dependent manner (Fig. 1B) . These data indicate that CORM-2 enhances the TTP promoter and thus increases TTP transcript level.
TTP Deficiency Abrogates the Anti-inflammatory Effect of CORM-2 in Macrophages
Our next goal was to determine whether TTP deficiency affects the anti-inflammatory effect of CORM-2 in macrophages. To test this, we treated peritoneal macrophages from wild-type and TTP KO mice with LPS in the presence or absence of CORM-2 and analyzed TNF-a expression by ELISA and RT-PCR. LPS treatment caused a significant increase in TNF-a in macrophages from both wild-type and TTP KO mice ( Figs. 2A and 2B) . However, although CORM-2 significantly inhibited the production of TNF-a induced by LPS in macrophages from wild-type mice, deficiency of TTP blocked the inhibitory effect of CORM-2 on LPS-induced production of TNF-a ( Figs. 2A and 2B ). These results suggest that TTP deficiency suppresses the anti-inflammatory effect of CORM-2 in macrophages.
We next determined whether CORM-2 could decrease the stability of TNF-a mRNA induced by LPS in macrophages. In macrophages from wild-type mice, CORM-2 treatment significantly decreased the stability of TNF-a mRNA (Fig. 2C) , indicating that the inhibitory effect of CORM-2 on the TNF-a production in macrophages results from enhancing the decay of TNF-a mRNA. To determine whether TTP deficiency affects the CORM-2-induced destabilization of TNF-a in macrophages, macrophages from TTP KO mice were treated with LPS in the presence or absence of CORM-2. In contrast to the macrophages from wild-type mice, CORM-2 treatment did not decrease the half-life of TNF-a mRNA in macrophages from TTP KO mice (Fig. 2C) , suggesting that TTP deficiency blocks the CORM-2-induced destabilization of TNF-a mRNA.
TTP Knockout Increases Susceptibility of Mice to DSSinduced Colitis
Administration of DSS increases the levels of pro-inflammatory cytokines [11] . Thus, it is possible to predict that TTP deficiency exacerbate DSS-induced colitis. To test this hypothesis, we assessed the effect of TTP knockout on intestinal inflammation in a DSS-induced colitis model. During the course of DSS treatment, TTP KO mice displayed a higher clinical score determined at day 12 after treatment (Fig. 3A) . Colon shortening, a macroscopic parameter of colitis severity, was more pronounced in DSS-treated TTP KO mice than in DSS-treated WT mice (colon length, 3.5060.13 cm vs. 4.0760.13 cm; Figs. 3B and 3C). No significant difference was observed in the colon length between untreated WT and TTP KO mice. In addition, histological study showed that DSS treatment resulted in greater loss of epithelial crypts and massive infiltration of inflammatory cells into the mucosa in TTP KO mice than in WT mice (Fig. 3D) . The activity of myeloperoxidase (MPO), a marker for neutrophil infiltration, in the colon of DSS-treated TTP KO mice was also increased compared with that in DSS-treated WT mice (Fig. 3E) . Next, we determined the effects of TTP deficiency on the DSS-induced production of inflammatory cytokines. It has been reported that DSS can develop colitis in the absence of TNF-a [24] . Thus, we analyzed the levels of pro-inflammatory cytokines including IL-6, CXCL1, and CXCL2 as well as TNF-a. As shown in Fig. 3F , TTP KO mice showed a marked increase in DSS-induced production of TNF-a, IL-6, CXCL1, and CXCL2 in colon tissues. Overall, these results demonstrate that TTP deficiency aggravates inflammation in a mouse model of colitis.
TTP is Required for the CO-mediated Protection Against DSS-induced Colitis
Based on our findings that CORM-2 increases TTP levels, and in turn, TTP mediates the anti-inflammatory effect of CORM-2 in macrophages and TTP deficiency exacerbates DSS-induced colitis, we hypothesized that exogenous CO and CO-RM may protect mice from DSS-induced colitis through a TTP-dependent mechanism. To assess whether TTP is required for the antiinflammatory effects of exogenous CO in DSS-induced colitis, we administered 2% DSS to wild-type mice and TTP KO mice with or without exposure to exogenous CO. CO inhalation treatment significantly decreased the levels of inflammatory cytokines (TNFa and IL-6) and chemokines (CXCL1 and CXCL2) induced by DSS in wild-type mice (Fig. 3F) . However, in TTP KO mice, the inhibitory effect of CO on the production of inflammatory cytokines and chemokines was blocked (Fig. 3F) . In addition, CO decreased the susceptibility of wild-type mice to DSS-induced colitis as determined by clinical score (Fig. 3A) , colon length (Figs. 3B and 3C) , and neutrophil infiltration (Figs. 3D and 3E) . However, in TTP KO mice, CO treatment did not change the severity of DSS-induced colitis in TTP KO mice (Figs. 3A-F) . Collectively, our data suggest that TTP is required for the antiinflammatory effect of CO in the DSS-induced colitis model.
Discussion
The administration of CO or CO-RMs can inhibit the production of inflammatory cytokines and protect animals against inflammatory diseases [3] . However, the basic mechanisms underlying the anti-inflammatory function of CO are not clear. In this study, we provide evidence that CO exerts its inhibitory effects through induction of TTP expression in macrophages; CORM-2 increases the TTP promoter activity and the expression of TTP, decreases the stability of TNF-a mRNA induced by LPS in a TTP-dependent manner, and CO decreases the levels of TNFa, IL-6, CXCL1, and CXCL2 induced by LPS, while TTP deficiency blocks the anti-inflammatory effect of CO. These results indicate that TTP induced by CO-RM mediates the antiinflammatory function of CO-RM in macrophages. Here we did not analyze the mechanisms for the CO-RM-induced expression of TTP. It has been reported that CO activates STAT3 [25] and STAT3 binds to TTP promoter region and induces TTP expression in macrophages [26] . Thus, it is possible to predict that the CO/STAT3 pathway enhances the TTP promoter activity and increases TTP expression. Further studies are required to elucidate the mechanisms involved in the induction of TTP by CO-RM.
The expression of inflammatory cytokines is associated with the development of intestinal inflammation in both animal models of colitis [27] and human IBD [28] . In the DSS-induced colitis model, expression of pro-inflammatory cytokines and chemokines is upregulated [11] . The mRNAs of these inflammatory cytokines contain AREs within their 39UTR, and their expression can be down-regulated by TTP [18] [19] [20] . Thus, mice lacking the TTP gene may lose their ability to down-regulate the production of inflammatory cytokines in response to tissue damage in the colon, resulting in exacerbated colitis. Consistently, we found that the TTP KO mice treated with DSS displayed increased susceptibility to colitis, decreased colon length, and increased neutrophil infiltration and expression of pro-inflammatory cytokines such as TNF-a, IL-6, CXCL1, and CXCL2 in the large intestinal mucosa. Considering the facts that these inflammatory cytokines are described for both animal models of colitis [27] and human IBD [28] , it is possible to predict that decreased level and/or activity of TTP in ulcerative colitis patients may lead to a defect in resolution of intestinal inflammation and exacerbated IBD symptoms.
It has been reported that CO-RM can protect against DSSinduced colitis [8] . The exacerbated colitis in TTP KO mice led us to test whether CO-RM can ameliorate DSS-induced colitis in TTP KO mice as well. Consistent with a previous report [8] , we observed that, in wild-type mice, CO ameliorated DSS-induced colitis by inhibition of neutrophil infiltration and inflammatory cytokine production. However, under conditions of CO exposure, TTP deficiency prevented the anti-inflammatory effect of CO in DSS-induced colitis. Previously it has been reported that HO-1 mediates the inhibitory effect of CO on chronic colitis [4] . Our data indicate that TTP is a key regulator of intestinal inflammatory diseases and CO-mediated anti-inflammatory function. Previously, it has been reported that TTP-knockout mice develop severe inflammatory arthritis, demonstrating the importance of TTP in limiting the inflammatory response [21] .
In conclusion, our study with an intestinal inflammation models shows that CO-mediated protection operates in part by inducing TTP, which leads to the down-regulation of inflammatory cytokines and chemokines. TTP deficiency exacerbates DSSinduced colitis and abrogates the protective effect of CO against DSS-induced colitis. Taken together, these data demonstrate for the first time a dependence on TTP in the CO-induced protection against DSS-induced colitis. The finding that TTP plays important roles in protection against DSS-induced colitis makes CO-TTP pathway an attractive candidate for the treatment of ulcerative colitis. 
